Correction: Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083763/
https://www.ncbi.nlm.nih.gov/pubmed/37024259
http://dx.doi.org/10.1136/bmjopen-2022-063650corr1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083763/
https://www.ncbi.nlm.nih.gov/pubmed/37024259
http://dx.doi.org/10.1136/bmjopen-2022-063650corr1

Ejemplares similares